Immunological therapy principles are increasingly determining modern medicine. They are
used to treat diseases of the immune system, for tumors, but also for infections,
neurological diseases, and many others. Most of these therapies base on antibodies,
but small molecules, soluble receptors or cells and modified cells are also used. The
development of immune checkpoint inhibitors is amazingly fast. T-cell directed antibody
therapies against PD-1 or CTLA-4 are already firmly established in the clinic. Further
targets are constantly being added and it is becoming increasingly clear that their
expression is not only relevant on T cells. Furthermore, we do not yet have any
experience with the long-term systemic effects of the treatment. Flow cytometry can be
used for diagnosis, monitoring, and detection of side effects. In this review, we focus on
checkpoint molecules as target molecules and functional markers of cells of the innate and
acquired immune system. However, for most of the interesting and potentially relevant
parameters, there are still no test kits suitable for routine use. Here we give an overview of
the detection of checkpoint molecules on immune cells in the peripheral blood and show
examples of a possible design of antibody panels.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84301 |
| Date | 24 March 2023 |
| Creators | Shibru, Benjamin, Fey, Katharina, Fricke, Stephan, Blaudszun, André-René, Fürst, Friederike, Weise, Max, Seiffert, Sabine, Weyh, Maria Katharina, Köhl, Ulrike, Sack, Ulrich, Boldt, Andreas |
| Publisher | Frontiers Research Foundation |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1664-3224, 694055 |
Page generated in 0.0016 seconds